| Gene symbol | LAMP3 | Synonyms | CD208, DC LAMP, DC-LAMP, DCLAMP, LAMP, LAMP-3, TSC403 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q27.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | lysosomal associated membrane protein 3 | ||||
| Gene symbol | UL83 | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_006273.2 | dbXrefs | |
| Description | tegument protein pp65 | ||||
| GTO ID | GTC1982 |
| Trial ID | NCT03688178 |
| Disease | Glioblastoma |
| Altered gene | UL83|LAMP |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | Human CMV pp65-LAMP mRNA-pulsed autologous DCs |
| Co-treatment | Temozolomide|Unpulsed DCs |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab |
| Year | 2020 |
| Country | United States |
| Company sponsor | Annick Desjardins, MD |
| Other ID(s) | Pro00082570 |
| Vector information | |||
|
|||
| Cohort1: Unpulsed DCs | |||||||||
|
|||||||||
| Cohort2: Td | |||||||||
|
|||||||||
| Cohort3: Varlilumab_Td | |||||||||
|
|||||||||